All In Biotech

Drug Trial Radar · NCT05952453

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 17, 2025

Primary completion

Oct 30, 2028

Study completion Dec 30, 2030

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

Conditions

  • Ovarian Cancer

Interventions

  • CarboplatinDrug

    neoadjuvant treatment , followed by surgery, then maintenance chemotherapy

  • olaparibp, embroDrug

    maintenance chemotherapy : olaparib, pembro

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center at UAB

    Birmingham, Alabama · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.